论文部分内容阅读
本文报道我院研制抗癌新药羧苯氮烯钠注射液(1-P-(3.3-DimethyL-1-trizeno)benzoicAcid Sodium简称CBDT-Na),观察95例晚期肺癌的疗效,其中男性73例,女性22例。年龄13-73岁(平均52.9岁)。临床诊断中心型肺癌52例,周围型43例。病理细胞学确诊86例,其中鳞癌25例,腺癌25例,未分化型13例,未定型癌23例。按临床分期:Ⅲ期42例,Ⅳ期53例,均合并转移。CBDT-Na用法:每次200-300mg加10％葡萄糖液500ml静滴,1日二次或隔日1次,总量6-9g。其中单纯使用61例,并用其他化疗药物23例,并用放疗11例。对照组20例,其中用其他化疗12例,化疗加放疗8例。治疗结果:CBDT-Na有效率为66.74％,对照组为50％。从病理类型看,认为腺癌部分缓解率高。随访71例,其中1年存活44例,生存率为61.97％,随访2年存活17例,生存率为23.94％。对照组随访16例,1年存活8例,生存率为50％,随访2年无1例存活。该药毒性反应甚少,未见过
This article reported that our hospital developed a new anticancer drug sodium benzophenone sodium injection (1-P-(3.3-DimethyL-1-trizeno) benzoic Acid Sodium referred to as CBDT-Na), observed 95 cases of advanced lung cancer, 73 cases of which male, 22 females. Age 13-73 (average 52.9 years old). Clinically diagnosed 52 cases of central lung cancer and 43 cases of peripheral type. 86 cases were diagnosed by pathological cytology, including 25 cases of squamous cell carcinoma, 25 cases of adenocarcinoma, 13 cases of undifferentiated carcinoma, and 23 cases of atypical carcinoma. According to the clinical stage: 42 cases of stage III, 53 cases of stage IV, all with metastasis. CBDT-Na usage: Each 200-300mg plus 10% glucose solution 500ml intravenous infusion, once a day or every other day, the total 6-9g. Among them, 61 cases were used alone, 23 cases were treated with other chemotherapy drugs, and 11 cases were treated with radiotherapy. The control group consisted of 20 patients, of whom 12 were treated with other chemotherapy and 8 were treated with chemotherapy and radiotherapy. Treatment results: The effective rate of CBDT-Na was 66.74%, and that of the control group was 50%. From the pathological type, it is considered that the partial remission rate of adenocarcinoma is high. Seventy-one patients were followed up, of which 44 survived 1 year. The survival rate was 61.97%. In the follow-up period of 2 years, 17 cases survived, and the survival rate was 23.94%. In the control group, 16 patients were followed up, 8 survived 1 year, and the survival rate was 50%. No patient survived after 2 years of follow-up. The drug has few toxic reactions and has not seen